Chinese pharmaceutical companies are developing domestic versions of “miracle” weight-loss drugs as they take on western drugmakers selling anti-obesity medication in one of the world’s biggest markets.
Chinese drug companies hope to compete with the Danish pharma group Novo Nordisk’s pioneering drugs in China, which has the world’s largest overweight and diabetic population. If successful, they could also potentially offer a cheaper alternative in the west.
The new generation of weight-loss drugs form part of a category called glucagon-like peptide-1 agonists or GLP-1s. Novo Nordisk’s semaglutide or Ozempic dominates the market, but dozens using the same mechanism are undergoing clinical trials in China, analysts said.
您已閱讀15%（727字），剩余85%（4280字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。